Please login to the form below

Not currently logged in
Email:
Password:

Takeda's diabetes drug enters phase III

Takeda Pharmaceutical's TAK-875, a novel investigational therapy for diabetes, has entered phase III development

Takeda Pharmaceutical's TAK-875, a novel investigational therapy for diabetes, has entered phase III development.

TAK-875 is being investigated for its ability as an agonist of GPR40, a receptor in pancreatic islet cells, with Takeda hoping it can selectively improve glucose-dependent insulin secretion with a potential for reduced risk of hypoglycaemia.

It is the first such drug to reach the phase III stage of development.

Dr Thomas Strack, vice president, clinical science, Takeda Global Research & Development Center, US, said: "Takeda is committed to enhancing the clinical investigation of TAK-875 in order to accelerate the development of a potential new type 2 diabetes treatment option for patients and healthcare professionals."

The first phase III trial in the US/Europe programme will enrol about 450 patients with type 2 diabetes who are not adequately controlled on diet and exercise. The study's primary endpoint will be the change in blood glucose levels at week 24.

19th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics